< Back to previous page
Researcher
Toon Van Gorp
- Disciplines:Cancer diagnosis, Cancer therapy, Oncological surgery, Cancer biology
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Oct 2019 → 30 Sep 2022
Projects
1 - 5 of 5
- Liquid biopsy and HRD testing in ovarian cancerFrom4 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- PPP2R1A as a new biomarker in type-II endometrial cancers.From1 Jan 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Predictive genetic markers for targeted therapy in gynaecological cancers: bridging the gap between “one-size-fits-all” and personalized treatmentFrom8 Oct 2020 → 30 Sep 2022Funding: BOF - projects
- Predictive genetic markers in gynaecological cancers: how to improve targeted therapy.From1 Oct 2020 → TodayFunding: FWO fundamental clinical research fellowship
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
Publications
11 - 20 of 137
- Reply to Z.R. McCaw et al.(2023)
Authors: Toon Van Gorp
Pages: 4705 - 4706 - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)(2023)
Authors: Toon Van Gorp
Pages: S517 - S517 - Atezolizumab (atezo) combined with platinum-based chemotherapy (CT) and maintenance niraparib for recurrent ovarian cancer (rOC) with a platinum-free interval (TFIp) >6 months: Primary analysis of the double-blind placebo (pbo)controlled ENGOT-Ov41/GEICO 69-O/ANITA phase III trial(2023)
Authors: Toon Van Gorp
Pages: S1278 - S1279 - Amyloid-like p53 as prognostic biomarker in serous ovarian cancer-a study of the OVCAD consortium(2023)
Authors: Ignace Vergote, Toon Van Gorp, Frederic Rousseau, Joost Schymkowitz
Pages: 2473 - 2484 - Randomized phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with or without nintedanib in first-line recurrent or advanced cervical cancer(2023)
Authors: Ignace Vergote, Els Van Nieuwenhuysen, Annouschka Laenen, Toon Van Gorp
Pages: 80 - 88 - PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial(2023)
Authors: Liselore Loverix, Ignace Vergote, Pieter Busschaert, Tom Venken, Bram Boeckx, Hilde Brems, Els Van Nieuwenhuysen, Thaïs Baert, Sileny Han, Patrick Neven, et al.
Pages: 131 - 139 - Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression(2023)
Authors: Toon Van Gorp
- The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer(2023)
Authors: Toon Van Gorp
- TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum(2023)
Authors: Toon Van Gorp
- Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study)(2023)
Authors: Toon Van Gorp